论文部分内容阅读
目的:观察TA方案治疗老年急性髓系白血病的疗效。方法:THP 20 mg/d静脉滴注,第1天~第3天,Ara-C 200 mg/d 分两次静脉滴注,间隔12 h,第1天~第5天或第1天~第7天;每疗程3周~ 4周。完全缓解后原方案巩固2个疗程,然后换用HA、EA和TA方案交替巩固和维持化疗。结果:20例中完全缓解(CR)13例(65 %),部分缓解(PR)3例,未缓解4例,总有效率80 %。结论:TA方案具有高效低毒特点,尤其适合老年急性髓系白血病选用其他蒽环类药物困难时采用。
Objective: To observe the efficacy of TA regimen in the treatment of senile acute myeloid leukemia. Methods: THP 20 mg / d was given intravenously. On the first day to the third day, Ara-C 200 mg / d was given intravenously twice a day for 12 hours, from day 1 to day 5 or from day 1 to day 7 days; each course of 3 weeks to 4 weeks. After complete remission of the original program to consolidate two courses, and then switch to HA, EA and TA program to alternately consolidate and maintain chemotherapy. Results: Of the 20 patients, complete remission (CR) occurred in 13 patients (65%), partial remission (PR) in 3 patients, unresponsiveness in 4 patients and total effective rate of 80%. Conclusion: The TA regimen has the characteristics of high efficiency and low toxicity, especially suitable for elderly patients with acute myeloid leukemia who use other anthracycline drugs.